BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 18622423)

  • 1. Determination of initial i.v. CYA dosage to achieve target AUC values in pediatric hematopoietic stem cell transplant patients.
    Jin M; Seto W; Taylor T; Saunders EF; Doyle J; Dupuis LL
    Bone Marrow Transplant; 2008 Oct; 42(7):455-9. PubMed ID: 18622423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of area under the whole blood concentration versus time curve after first intravenous cyclosporine dose in children undergoing hematopoietic stem cell transplant: limited sampling strategies.
    Sibbald C; Seto W; Taylor T; Saunders EF; Doyle J; Dupuis LL
    Ther Drug Monit; 2008 Aug; 30(4):434-8. PubMed ID: 18641547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
    Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus clearance is age-dependent within the pediatric population.
    Przepiorka D; Blamble D; Hilsenbeck S; Danielson M; Krance R; Chan KW
    Bone Marrow Transplant; 2000 Sep; 26(6):601-5. PubMed ID: 11041564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.
    Barkholt L; Remberger M; Bodegård H; Ringdén O; Böttiger Y
    Bone Marrow Transplant; 2007 Oct; 40(7):683-9. PubMed ID: 17660840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy.
    Nakamura Y; Takeuchi H; Okuyama K; Akashi T; Jojima Y; Konno O; Akashi I; Hama K; Iwahori T; Ashizawa T; Hirano T; Oka K; Matsuno N; Nagao T
    Transplant Proc; 2005 May; 37(4):1725-7. PubMed ID: 15919445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of cyclosporine A at a high-peak concentration of twice-daily infusion and oral administration in allogeneic haematopoietic stem cell transplantation.
    Inoue Y; Saito T; Ogawa K; Nishio Y; Kosugi S; Suzuki Y; Shibuya Y; Kato M; Takahashi M; Miura I
    J Clin Pharm Ther; 2011 Aug; 36(4):518-24. PubMed ID: 21105879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of area under the cyclosporine concentration versus time curve in children undergoing hematopoietic stem cell transplantation.
    Dupuis LL; Seto W; Teuffel O; Gibson P; Schultz KR; Doyle JD; Gassas A; Egeler RM; Sung L; Schechter T
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):418-23. PubMed ID: 23128321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CsA exposure is associated with acute GVHD and relapse in children after SCT.
    Willemze AJ; Press RR; Lankester AC; Egeler RM; den Hartigh J; Vossen JM
    Bone Marrow Transplant; 2010 Jun; 45(6):1056-61. PubMed ID: 19881556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of limited sampling strategies for estimation of cyclosporine area under the concentration-time curve in hematopoietic stem cell transplant patients.
    Hadjibabaie M; Vazirian I; Iravani M; Moosavi SA; Alimoghaddam K; Ghavamzadeh A; Rezaee S
    Ther Drug Monit; 2011 Dec; 33(6):673-80. PubMed ID: 22011723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of converting from intravenous to oral administration of cyclosporin A in pediatric allogeneic hematopoietic stem cell transplant recipients.
    Choi JS; Lee SH; Chung SJ; Yoo KH; Sung KW; Koo HH
    Bone Marrow Transplant; 2006 Jul; 38(1):29-35. PubMed ID: 16715103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients. The trough level is not enough.
    Schrauder A; Saleh S; Sykora KW; Hoy H; Welte K; Boos J; Hempel G; Grigull L
    Pediatr Transplant; 2009 Jun; 13(4):444-50. PubMed ID: 18482216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation.
    Hangler HB; Ruttmann E; Geltner C; Bucher B; Nagiller J; Laufer G; Mueller LC
    Clin Transplant; 2008; 22(1):35-40. PubMed ID: 18217903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters.
    Takeuchi H; Okuyama K; Konno O; Jojima Y; Akashi I; Nakamura Y; Iwamoto H; Hama K; Iwahori T; Uchiyama M; Ashizawa T; Matsuno N; Nagao T; Hirano T; Oka K
    Transplant Proc; 2005 May; 37(4):1745-7. PubMed ID: 15919452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cyclosporine a conversion from twice-daily infusion to oral administration in allogeneic hematopoietic stem cell transplantation.
    Inoue Y; Saito T; Ogawa K; Nishio Y; Kosugi S; Suzuki Y; Kato M; Sakai H; Takahashi M; Miura I
    Am J Ther; 2014; 21(5):377-84. PubMed ID: 23011175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective appraisal of busulfan dose adjustment in children.
    Dupuis LL; Najdova M; Saunders EF
    Bone Marrow Transplant; 2000 Dec; 26(11):1143-7. PubMed ID: 11149723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of CsA during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation.
    Kimura S; Oshima K; Okuda S; Sato K; Sato M; Terasako K; Nakasone H; Kako S; Yamazaki R; Tanaka Y; Tanihara A; Higuchi T; Nishida J; Kanda Y
    Bone Marrow Transplant; 2010 Jun; 45(6):1088-94. PubMed ID: 19898510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achievement of target cyclosporine concentrations as a predictor of severe acute graft versus host disease in children undergoing hematopoietic stem cell transplantation and receiving cyclosporine and methotrexate prophylaxis.
    Punnett A; Sung L; Price V; Das P; Diezi M; Doyle J; Dupuis LL
    Ther Drug Monit; 2007 Dec; 29(6):750-7. PubMed ID: 18043472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of intravenous cyclosporine area under the concentration-time curve after allogeneic stem cell transplantation.
    Duncan N; Arrazi J; Nagra S; Cook M; Thomson AH; Craddock C
    Ther Drug Monit; 2010 Jun; 32(3):353-8. PubMed ID: 20224513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
    Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
    Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.